CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee.
Mr. O’Boyle previously served as a director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ). In addition to Carlsmed, he currently serves on the board of Nevro (NVRO). Mr. O’Boyle has over 20 years of executive management experience and 14 years of board of director experience in the medical device industry.
“With his decades of financial governance expertise in the medical technology industry, Kevin is a valuable addition to our experienced Board of Directors,” states Mike Cordonnier, CEO and Chairman of Carlsmed. “The addition of Kevin to the Board is another step forward for our Company and comes on the heels of several significant accomplishments.”
In August, the Company shared that compelling clinical data was published demonstrating lower rates of revision surgery for spine surgery procedures utilizing personalized interbody devices. The special issue, “Personalized Medicine in Spine Surgery,” published by the International Journal of Spine Surgery, is available HERE.
The Company also announced that as of October 1, spine fusion procedures using its aprevo® patient-specific devices will be assigned to the highest level of Medicare Severity-Diagnosis Related Groups (MS-DRG), resulting in more favorable reimbursement on average.
According to Mr. Cordonnier, “The mounting clinical evidence in support of aprevo patient-specific solutions for spine surgery, combined with favorable reimbursement, points toward a future in which personalized spine surgery is the standard of care and the first choice for patients.”
About Carlsmed
Carlsmed is a commercial stage technology company and leader of the personalized spine surgery market. aprevo® is the only commercially available custom made anatomically designed interbody for spine fusion surgery.
